RULING FOR SHIRE MAY SIGNAL STRONGER PATENT PROTECTION IN CANADA
Does a Canadian court’s support of Shire’s patent on its abuse-resistant ADHD drug confirm a trend of stronger pharmaceutical patent protection in the country?
The Federal Court recently ruled in favor of Shire LLC’s patent for Vyvanse (lisdexamfetamine) against invalidity claims by generic manufacturer Apotex Inc.
At the same time, the court rejected Shire’s claims that Apotex infringed the patent by producing a significant quantity of generic product for research and regulatory uses.
Peter Menyasz speaks to patent lawyers about the delicate balance between patent protection and ensuring access to ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.